Orexin receptors: a journey through their discovery to the development of suvorexant, the new sleeping pill
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20161493Keywords:
OX receptors, Hypocretin receptors, Insomnia, Suvorexant, NeuropeptideAbstract
Orexin (OX) neuropeptides acting through G-protein coupled OX1 and OX2 receptors are implicated in a variety of physiological roles including regulation of feeding, sleep-wake cycle, energy metabolism and reward pathways. Accumulating experimental evidence indicates that orexins are wake promoting neuropeptides and deficits in orexinergic neurotransmission leads to narcolepsy, a debilitating sleep disorder. This has led to a search for orexin receptor agonists for pharmacotherapy of narcolepsy. However, development of orexin receptor agonists are still in their infancy stage and it invokes further research to know whether it could turn into a reality. In addition, the role of orexin neuropeptides in promoting arousal and wakefulness has generated considerable interest in developing orexin receptor antagonists for treatment of insomnia. This quest was accomplished with the approval of suvorexant by United States food and drug administration in 2014. This remarkable discovery has opened a novel approach for treatment of insomnia through neuromodulation of orexin signaling. Hence this review focuses on the orexinergic system, their physiological action and potential role as pharmacological targets.
References
De LL, Kilduff TS, Peyron C, Gao XB, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci. 1998;95:322-7.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-85.
Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International union of basic and clinical pharmacology. orexin receptor function, nomenclature and pharmacology. Pharmacol Rev.2012;64:389-420.
Kukkonen JP, Holmqvist T, Ammoun S, Akerman KEO. Functions of the orexinergic/hypocretinergic system. AJP Cell Physiol. 2002;283:567-91.
De LL, Huerta R. Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;5:16.
Karteris E, Machado RJ, Chen J, Zervou S, Willhouse EW, Randeva HS. Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. AJP Endocrinol Metab. 2005;288:1089-100.
Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KEO, Kukkonen JP. OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. J Biol Chem. 2005;280:6570-9.
Urbańska A, Sokołowska P, Woldan TA, Biegańska K, Brix B, Jöhren O, et al. orexins/hypocretins acting at gi protein-coupled OX2 receptors inhibit cyclic amp synthesis in the primary neuronal cultures. J Mol Neurosci. 2012;46:10-7.
Jantti M, Putula J, Somerharju P, Frohman M, Kukkonen J. OX1 orexin/hypocretin receptor activation of phospholipase D: OX1 activates PLD. Br J Pharmacol. 2012;165:1109-23.
Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol. 2014;171:294-313.
Lee MG. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005;25:6716-20.
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345-54.
Chou TC, Lee CE, Lu J, Elmquist JK, Hara J, Willie JT, et al. Orexin (hypocretin) neurons contain dynorphin. J Neurosci. 2001;21:1-6.
Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci. 2014;111:1648-55.
Flores Á, Valls CV, Costa G, Saravia R, Maldonado R, Berrendero F. The hypocretin/orexin system mediates the extinction of fear memories. Neuro Psychopharmacology. 2014;39:2732-41.
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437-51.
Hasegawa E, Yanagisawa M, Sakurai T, Mieda M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest. 2014;124:604-16.
Mahlios J, De HA, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol. 2013;23:767-73.
Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50:381-8.
Heifetz A, Bodkin MJ, Biggin PC. Discovery of the first selective, nonpeptidic orexin2 receptor agonists. J Med Chem. 2015;58:7928-30.
Nagahara T, Saitoh T, Kutsumura N, Irukayama-Tomobe Y, Ogawa Y, Kuroda D, et al. design and synthesis of non-peptide, selective orexin receptor 2 agonists. J Med Chem. 2015;58:7931-7.
Equihua AC, De HA, Drucker CR. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol. 2013;4:163.
Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171:283-93.
Bennett T, Bray D, Neville MW. Suvorexant, a dual orexin receptor antagonist for the management of insomnia. Physical Therapy J. 2014;39:265-6.
Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf. 2015;6:189-95.
Kishi T, Matsunaga S, Iwata N. Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. Plos One. 2015;10:0136910.
